子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 81 | Quinone derivative | JP23705190 | 1990-09-10 | JPH03188042A | 1991-08-16 | ABE SHINYA; OKAMOTO YASUSHI; TAGAMI KATSUYA; HIBI SHIGEKI; NAGAGAWA JUNICHI; HIROTA KAZUO; HISHINUMA TAKAHARU; MIYAMOTO KANAME; YAMANAKA TEIJI; YOKOHAMA HIROMITSU; YOSHIMURA TSUTOMU; HORIE TORU; AKITA HASHINORI; KATAYAMA KOICHI; YAMATSU ISAO |
| NEW MATERIAL:A compound expressed by formula I {A is formula II, formula III [R 3 to R 5 are H, alkyl or alkoxy; X and Y are OH or formula IV (n is 0 or 1; R 6 is alkyl)]; R 1 is alkyl, cycloalkyl, alkenyl, alkynyl, arylalkyl, (CH 2) 1-10-CN, etc.; R2 is O-R 8 (R 8 is H or alkyl), NR 9R 10 (R 9 and R 10 are H, alkyl, heteroaryl, etc.)} or salt thereof. EXAMPLE: (E)-3-[5-(6-Methyl-1-methoxymethyloxy-2, 3, 4-trimethoxy) phenyl]-2- nonyl-2-propenoic acid. USE: A remedy for lever disease. PREPARATION: For example, an aldehyde derivative expressed by formula V is subjected to Wittig reaction with a posphonate expressed by formula Vl in the presence of a base to provide the compound expressed by formula I (A is formula III). COPYRIGHT: (C)1991,JPO&Japio | ||||||
| 82 | JPH0335306B2 - | JP2379884 | 1984-02-10 | JPH0335306B2 | 1991-05-27 | HASHIMOTO KINJI; GOTO KYOTO; TSUDA YOSHIAKI |
| 83 | Cyclocondensation quinone derivative | JP2186388 | 1988-02-03 | JPH01197453A | 1989-08-09 | TATSUOKA TOSHIO; SUZUKI KENJI; SATO FUMIO; MIYANO SEIJI; SUMOTO KUNIHIRO |
| NEW MATERIAL:A cyclocondensation quinone derivative shown by formula I (R 1, R 2 and R 3 are H, methyl or methoxy; R 4 is hydroxymethyl or carboxyl which may be amidated or esterified; X is H, halogen, lower alkyl or methoxy; Y is CH 2 or O) or a hydroquinone derivative thereof. EXAMPLE: 1,2,3,4-Tetrahydro-4-(3,4-dimethoxy-6-methyl-2,5-benzoquinonyl)-2- naphthoic acid. USE: A drug useful for improving and treating diseases based on organic disorder in the brain. A small of the drug is orally administered. Low toxicity. PREPARATION: For example, a substituted benzaldehyde is reacted with succinic anhydride to give a butyrolactonecarboxylic acid derivative shown by formula II, which is esterified, reduced and then subjected to ring closure to give a tetralone derivative shown by formula IV. This derivative is reduced and treated with a dehydrating condensation agent to give a lactone shown by formula VI, which is condensed with a hydroquinone derivative shown by formula VII to give a compound shown by formula I wherein Y=CH 2. COPYRIGHT: (C)1989,JPO&Japio | ||||||
| 84 | JPH0120126B2 - | JP1462887 | 1987-01-23 | JPH0120126B2 | 1989-04-14 | IMADA ISUKE; TERAO SHINJI; KAWADA MITSURU; SHIRAISHI MITSURU |
| 85 | Remedy for hepatic disease | JP1936587 | 1987-01-28 | JPS63185921A | 1988-08-01 | MIZOGUCHI YASUHIRO; MAKI YOSHITAKA |
| PURPOSE: To obtain a remedy for hepatic diseases, by using a quinone derivative or its hydroquinone compound as an active component. CONSTITUTION: The objective remedy for hepatic diseases contains a compound of formula (R 1 and R 2 are methyl, methoxy or together form -CH=CH-CH=CH-; R 3 is methyl, hydroxymethyl or (esterified) carboxyl; Z is -C≡C- or -CH=CH-; m and n are 0W10; k is 1W5; when n is 2 or 3, Z and k may be arbitrarily varied in the recurring unit in the parentheses [ ]) or its hydroquinone compound as an active component. Since the compound of formula has strong 5- lipoxygenase-inhibiting and antioxidation effects and low toxicity, it is useful for the prevention and remedy of chronic heptatitis, fulminant hepatitis, hepatofibrosis, hepatocirrhosis, alcoholic hepatitis, etc. It is administered by oral or parenteral administration preferably at a rate of 0.2W20mg/kg per dose and 1W3 doses daily. COPYRIGHT: (C)1988,JPO&Japio | ||||||
| 86 | Thromboxane a2 receptor antagonist | JP24790086 | 1986-10-17 | JPS63101322A | 1988-05-06 | TERAO SHINJI; NISHIKAWA KOHEI |
| PURPOSE: To provide the titled antagonist containing a quinone derivative having bulky group on the α-carbon of a side chain or its hydroquinone compound as an active component, resistant to inactivation by metabolism in living body and capable of keeping effective drug concentration in blood over a long period. CONSTITUTION: The objective agent contains a quinone derivative of formula [R 1 and R 2 are methyl, methoxy or together form -CH=CH-CH=CH-; R 3 is (substituted) phenyl, naphthyl or thienyl; R 4 is carboxyl or a group which can be converted to carboxyl group in living body; n is 3W15] or its hydroquinone compound, e.g. 7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid, as an active component. The agent is useful as a remedy and preventive for diseases caused by the insulfficiency or disorder of the function of circulation system or peripheral circulation system. It is convenient to administer 0.1W20mg/kg weight of the active component once or twice a day in the case of oral administration to an adult patient. COPYRIGHT: (C)1988,JPO&Japio | ||||||
| 87 | JPS6247176B2 - | JP11777179 | 1979-09-12 | JPS6247176B2 | 1987-10-06 | TERAO SHINJI; SHIRAISHI MITSURU; KATO KANEYOSHI |
| 88 | Medicine containing quinone compound as active component | JP1462887 | 1987-01-23 | JPS62174010A | 1987-07-30 | IMADA ISUKE; TERAO SHINJI; KAWADA MITSURU; SHIRAISHI MITSURU |
| PURPOSE: To provide a medicine containing a specific quinone compound as an active component, having excellent characteristics such as low toxicity and fat-solubility and high absorbability and useful as a hypotensor, remedy for cardiopathy, bronchodilator, cerebul circulation improver, etc. CONSTITUTION: The objective medicine contains, as an active component, the compound of formula I [the α-β bond is a) saturated bond or b) double bond; R is CH 3, OCH 3 or two R groups together form CH=CHCH=CH; n is integer of 0W9; R 2 is H or OH when the bond α-β is a) and is H when the bond is b); R 1 is COOH, (CH 2) mOH or group of formula II when the α-β bond is b) or R 2 is OH or R 1 is CH 2OH or group of formula II when the bond α-β is a) and R 2 is H; m is 1, 2 or 3]. The compound has various pharmacological activities such as bio-membrane stabilizing action, electron-transfer action, hypotensive action, cardiomegalyinhibiting action, bronchial muscule relaxing action, cerebral circulation improving action, cerebral ischemia preventive action, etc., and is useful as the above medicines for the prevention and remedy of hypertension, cardiac insufficiency, asthma, cerebral apoplexy, etc. COPYRIGHT: (C)1987,JPO&Japio | ||||||
| 89 | JPS61501388A - | JP50393084 | 1984-10-19 | JPS61501388A | 1986-07-10 | |
| 90 | Quinone derivative | JP17052085 | 1985-07-31 | JPS6144840A | 1986-03-04 | TERAO SHINJI; MAKI YOSHITAKA |
| NEW MATERIAL:The quinone derivative or hydroquinone compound of formula I (R<1> and R<2> are H, methyl or methoxy, or R<1> and R<2> together form -CH= CH-CH=CH-; R<3> is H or methyl; R<4> is (substituted) aliphatic group, aromatic group or heterocyclic group; R<5> is methyl, methoxy, hydroxymethyl or carboxy; Z is C=C, CH=CH, group of formula II, formula III, etc.; n is 0-10; m is 0-3; k is 0-5). EXAMPLE:6-(3,5,6-Trimethyl-1,4-benzoquinon-2-yl)-6-(2-thienyl)hexanoic acid ethyl ester. USE:Antiasthmic agent, antiallergic agent or cerebral cardio-vascular system improver. PREPARATION:The compound of formula I can be prepared by reacting the compound of formula II (R<6> is H, methyl, methoxymethyl, benzyl, etc.; R<7> is H, OH, methoxy, methoxymethyloxy, etc.) with an oxidizing agent. | ||||||
| 91 | Quinone compound | JP10137083 | 1983-06-06 | JPS59225138A | 1984-12-18 | TERAO SHINJI; MAKI YOSHITAKA |
| NEW MATERIAL:A quinone compound shown by the formula I (R is methyl, or methoxy; Y is formyl, carboxyl, 2W5C alkoxycarbonyl, carbamoyl, mono- or di- 1W4C alkylcarbamoyl, or carbamoyloxymethyl group) or its hydroquinone derivative. EXAMPLE: 2,3,5-Trimethyl-6-(11-carboxyundecane-5,10-diynyl)-1,4-hydroquinone. USE: Having inhibitory action on production of particularly fatty acid peroxide, inhibitory action on production of SRS-A (slow reacting substance of anaphylaxis), useful as a drug such as antiasthmatic, antiallergic, hypotensor, antiulcer, diuretic, etc. PREPARATION: For example, a compound shown by the formula II (R 1 is lower alkyl, benzyl group, etc.) is deprotected, to give a compound shown by the formula I . COPYRIGHT: (C)1984,JPO&Japio | ||||||
| 92 | Novel 1,4-benzoquinones | JP7415583 | 1983-04-28 | JPS58203935A | 1983-11-28 | FUREDERITSUKU HARORUDO HAUERU |
| 93 | Benzoquinone derivative | JP6222482 | 1982-04-13 | JPS58177934A | 1983-10-18 | TERAO SHINJI; OKAZAKI NAOYOSHI; IMADA ISUKE |
| NEW MATERIAL:The benzoquinone derivative of formula I [R 1 and R 2 are methyl or methoxy; n is 0W21; m is 0 or 1; Z is CH 2N(R 3)R 4 [R 3 and R 4 are H, alkyl or morpholino of N(R 3)R 4], COR 5 (R 5 is α-amino acid residue or glucosamine residue), group of formula II (R 6 is residue of bivalent hydrocarbon), formula III or formula IV (l is 1W4; R 7 is OH, methoxy or methyl]. EXAMPLE: 3-(2,4-Dimethoxy-5-methyl-1,4-benzoquinon-6-yl)propionylglycine. USE: Pharmaceuticals having protocollagen-proline hydrolase-inhibiting and collagen biosynthesis-suppressing activities, etc. Remedy for arteriosclerosis, hepatocirrhosis, scleroderma, keroid, nodose rheumatism, etc. PROCESS: The compound of formula I can be prepared e.g. by oxidizing the compound of formula V [X is H or (protected) OH; Y is (protected) OH] if necessary after removing the protecting group. COPYRIGHT: (C)1983,JPO&Japio | ||||||
| 94 | Quinones and their preparation | JP4995680 | 1980-04-15 | JPS56147746A | 1981-11-16 | IMADA ISUKE; OKUYA TETSUYA; WATANABE MASAZUMI |
| NEW MATERIAL:A compound shown by the formula I (n is 10W21; R is H or lower alkyl). EXAMPLE: 2, 3-Dimethoxy-6-( 12-methoxycarbonyldodecyl )-5-methyl-1, 4-bezoquinone. USE: Having hypotensive actions, tissue metabolism activating actions, immune adjusting actions, lysosome membrane stabilizing actions, and SRS-A actions, useful as a remedy for cardiac incompetence, remedy for cerebral circulation disorder, immune adjusting agent, and antiallergic agent. PROCESS: A compound shown by the formula II is reacted with a peroxide of a compound shown by the formula III or its anhydride in an inert solvent, e.g., n-hexane, etc. at 80W100°C, to give a compound shown by the formula I. Forms of drugs are capsules, granules, powder, tablets, etc., and the antiallergic agent is an ointment, aerosol, inhalant, etc. A dose per adult a day is 5W500mg. COPYRIGHT: (C)1981,JPO&Japio | ||||||
| 95 | 1,4-naphthoquinone derivative, its preparation, and its use | JP2967580 | 1980-03-06 | JPS56125335A | 1981-10-01 | IKUSHIMA KOUICHI; TANAKA HIROKAZU; OOE OSAMU; IGUCHI HIDEKO; MUKOUZAKA MASANOBU; AOKI HATSUO; ARAKAWA HIROSHI; IMANAKA HIROSHI |
| NEW MATERIAL:A 1,4-naphthoquinone derivative of formula I [R<1> is H, OH, lower alkoxy, or arylthio; R<2> is carboxy, esterified carboxy, or amidated carboxy; or R<1> and R<2> together form -O-C(=O)-; R<3> is H or lower alkyl; R<4> is lower alkyl; R<5> is H or halogen; R<6> is H, lower alkyl, or lower alkanoyl], or its salt at the carboxyl group. EXAMPLE:8-Hydroxy-1-methoxy-3-methyl-7,12-dihydro-5H-benzo[d]naphtho [2,3-b] pyran-5,7,12-trione. USE:Preventive and remedy for coccidiosis. PROCESS:The compound of formula I' (R<1> and R<2> particular groups defined in the formula I) is separated from the cultured product obtained by culturing bacteria belonging to Streptomyces genus and capable of producing the compound of formula I', e.g. Streptomyces auranticolor No.5995, in a culturing medium. | ||||||
| 96 | Quinone compound and its preparation | JP11777179 | 1979-09-12 | JPS5640651A | 1981-04-16 | TERAO SHINJI; SHIRAISHI MITSURU; KATOU KANEYOSHI |
| NEW MATERIAL:A compound of formula I (n is an integer 1W10; R 1 is methyl, methoxy, or two R 1s form -CH=CH-CH=CH-; R 2 is amino) or a hydroquinone form thereof. EXAMPLE: The compound of formula II (n is 1; R 2 is a group of formula III). USE: A hypotensive agent, an analgesic agent, an antitumor agent, an anti-inflammatory agent, a diuretic agent and an immune regulator having a regulating action on biosynthesis of prostaglandin, an inhibitory action on SRS-A (a slow-reacting substance of anaphylaxis) and an adrenergic blocking action. PROCESS: A carboxylic acid of formula IV or V or a reactive derivative at the carboxyl group thereof is reacted with a compound of the formula R 2-H in the presence of an active condensing agent, e.g. N,N'-dicyclohexylcarbodiimide, in an organic solvent, e.g. dichloromethane, at -20W150°C to give the compound of formula I. COPYRIGHT: (C)1981,JPO&Japio | ||||||
| 97 | JPS50148325A - | JP5000374 | 1974-05-02 | JPS50148325A | 1975-11-27 | |
| 98 | JPS5026529B1 - | JP8762270 | 1970-10-06 | JPS5026529B1 | 1975-09-01 | |
| 99 | JPS5095244A - | JP151974 | 1973-12-25 | JPS5095244A | 1975-07-29 | |
| 100 | JPS5010574B1 - | JP6693870 | 1970-07-30 | JPS5010574B1 | 1975-04-22 | |
QQ群二维码
意见反馈
意见反馈